Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03 Meeting Abstract
| Authors: | Saura, C.; Cortés, J.; Modi, S.; Kim, S. B.; Hamilton, E. P.; Hurvitz, S. A.; Krop, I. E.; Curigliano, G.; Iwata, H.; Im, S. A.; Herbolsheimer, P. M.; Karnoub, M.; Gambhire, D.; Egorov, A.; Andre, F. |
| Abstract Title: | Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03 |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400133 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.1023 |
| Notes: | Meeting Abstract: 1023 -- Source: Wos |
